Comparative efficacy of switching to natalizumab in active multiple sclerosis

Timothy Spelman, Tomas Kalincik, Annie Zhang, Fabio Pellegrini, Heinz Wiendl, Ludwig Kappos, Larisa Tsvetkova, Shibeshih Belachew, Robert Hyde, Freek Verheul, Francois Grand-Maison, Guillermo Izquierdo, Pierre Grammond, Pierre Duquette, Alessandra Lugaresi, Jeannette Lechner-Scott, Celia Oreja-Guevara, Raymond Hupperts, Thor Petersen, Michael BarnettMaria Trojano, Helmut Butzkueven

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)373-387
JournalAnnals of Clinical and Translational Neurology
Volume2
Issue number4
DOIs
Publication statusPublished - Apr 2015

Cite this

Spelman, T., Kalincik, T., Zhang, A., Pellegrini, F., Wiendl, H., Kappos, L., Tsvetkova, L., Belachew, S., Hyde, R., Verheul, F., Grand-Maison, F., Izquierdo, G., Grammond, P., Duquette, P., Lugaresi, A., Lechner-Scott, J., Oreja-Guevara, C., Hupperts, R., Petersen, T., ... Butzkueven, H. (2015). Comparative efficacy of switching to natalizumab in active multiple sclerosis. Annals of Clinical and Translational Neurology, 2(4), 373-387. https://doi.org/10.1002/acn3.180